TNF Inhibitor denied for failing step therapy by Highmark?

Highmark uses Prime Therapeutics PBM. Adalimumab biosimilar preferred (Cyltezo/Hyrimoz/Yusimry). Step therapy through preferred biosimilar required for new starts; existing patients on Humira may grandfather.

Highmark Continuity of Care provisions — 90-day grandfather for established therapy. Cite Prime Therapeutics PA exception process. ACR 2019 Position Statement opposes non-medical switching of stable patients.

## Why Highmark Requires Step Therapy for TNF Inhibitors — and Why You Can Appeal

TNF inhibitors are effective but costly biologic medications prescribed for conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease, and psoriasis. Highmark's step-therapy (also called "fail-first") policy requires that patients try and document inadequate response to one or more preferred, lower-cost medications before TNF inhibitor coverage will be approved. A step-therapy denial means Highmark believes its required prior-step medications have not been adequately trialed.

## Why This Is Appealable

Step-therapy protocols have widely recognized exceptions. If you have already tried the required prior-step drugs and failed, experienced intolerance, or have a documented contraindication, you may qualify for a step-therapy exception. Even if you are new to treatment, your prescriber may be able to demonstrate why starting directly on a TNF inhibitor is medically necessary — for example, due to disease severity, comorbidities, or clinical features that make prior-step drugs inappropriate. Under ACA §2719 and ERISA §503, you are entitled to a full-and-fair internal review and, if unsuccessful, an independent external review. External review is typically available within approximately four months of denial, with an expedited option when delay would jeopardize your health.

## The Appeal Process and Timeline

1. Obtain the denial letter: confirm which specific step-therapy requirements Highmark says were not met. 2. File a step-therapy exception request or internal appeal: Highmark's member materials specify the deadline. Many states have enacted step-therapy exception laws requiring insurers to respond quickly — check whether Pennsylvania law or your plan type provides additional protections. 3. Escalate to external review if the internal appeal is denied. 4. Request expedited review if your prescriber certifies that waiting would seriously harm your health.

## Documentation to Gather

• Prior treatment records: for every required prior-step medication, gather pharmacy records, prescriber notes, and documented dates of trials. Note the reason each was stopped — inadequate response, adverse effect, or clinical contraindication.
• Diagnosis and severity documentation: current chart notes, specialist evaluations, lab results, and imaging that establish your diagnosis and disease activity level.
• Prescriber's step-therapy exception letter: your physician should address each required prior step explicitly, explaining why the step was completed, not appropriate, or why your clinical situation justifies bypassing it.
• FDA-approved prescribing label for the TNF inhibitor: confirms the approved indication your prescription is based on.
• Highmark's published step-therapy policy: request this document and map each requirement to your evidence.

## Criteria-Mapping Structure

Address each policy step directly:

| Step-Therapy Requirement | Evidence of Completion or Exception | |---|---| | Prior-step drug 1 trialed | [Dates, pharmacy records, outcome] | | Prior-step drug 2 trialed (if required) | [Dates, pharmacy records, outcome] | | Clinical exception criteria | [Prescriber letter explaining medical basis] | | TNF inhibitor indication confirmed | [Diagnosis, label indication] |

A well-documented step-by-step response is the most effective way to overcome a step-therapy denial.